Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Duke University Medical Center Duke - Baker
mi
from
Durham, NC
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Duke University Medical Center Duke - Baker
mi
from
Durham, NC
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Willamette Valley Clinical Studies Williamette Valley Cancer
mi
from
Eugene, OR
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Willamette Valley Clinical Studies Williamette Valley Cancer
mi
from
Eugene, OR
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Fox Chase Cancer Center FCCC
mi
from
Philadelphia, PA
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Fox Chase Cancer Center FCCC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Sammons Cancer Center - Texas Oncology SC-2
mi
from
Dallas, TX
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Sammons Cancer Center - Texas Oncology SC-2
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
University of Texas/MD Anderson Cancer Center SC-3
mi
from
Houston, TX
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
University of Texas/MD Anderson Cancer Center SC-3
mi
from
Houston, TX
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Northwest Cancer Specialists Northwest Cancer
mi
from
Portland, OR
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Northwest Cancer Specialists Northwest Cancer
mi
from
Portland, OR
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Texas Oncology Midtown Texas Oncology
mi
from
Dallas, TX
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Texas Oncology Midtown Texas Oncology
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  2/18/2016
Novartis Investigative Site
mi
from
Parkville,
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 2/18/2016
Novartis Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
Status: Enrolling
Updated:  2/25/2016
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
Status: Enrolling
Updated: 2/25/2016
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
Status: Enrolling
Updated:  2/25/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
Status: Enrolling
Updated: 2/25/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
Status: Enrolling
Updated:  2/25/2016
Northwestern University
mi
from
Chicago, IL
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
Status: Enrolling
Updated: 2/25/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  2/25/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 2/25/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Sutter East Bay Neuroscience Institute-Eden Medical Center
mi
from
Castro Valley, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Sutter East Bay Neuroscience Institute-Eden Medical Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Kaiser Permanente Los Angeles
mi
from
Los Angeles, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Kaiser Permanente Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
St. Joseph Hospital of Orange
mi
from
Orange, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
St. Joseph Hospital of Orange
mi
from
Orange, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of California, Irvine Medical Center
mi
from
Orange, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Kaiser Permanente-Redwood City
mi
from
Redwood City, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Kaiser Permanente-Redwood City
mi
from
Redwood City, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Sutter Institute for Medical Research
mi
from
Sacramento, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Sutter Institute for Medical Research
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Colorado Neurological Institute
mi
from
Englewood, CO
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Colorado Neurological Institute
mi
from
Englewood, CO
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Georgetown University Medical Center
mi
from
Washington,
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Florida
mi
from
Gainesville, FL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Memorial Cancer Institute
mi
from
Hollywood, FL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Memorial Cancer Institute
mi
from
Hollywood, FL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Mount Sinai Community Clinical Oncology Program
mi
from
Miami Beach, FL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Mount Sinai Community Clinical Oncology Program
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Piedmont Atlanta Hospital
mi
from
Atlanta, GA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Piedmont Atlanta Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Rush University Medical Center
mi
from
Chicago, IL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Illinois Cancer Care
mi
from
Peoria, IL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Cadence Cancer Center
mi
from
Warrenville, IL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Cadence Cancer Center
mi
from
Warrenville, IL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
IU Simon Cancer Center
mi
from
Indianapolis, IN
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
IU Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Kansas Cancer Center
mi
from
Westwood, KA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Markey Cancer Center-University of Kentucky
mi
from
Lexington, KY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Markey Cancer Center-University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Norton Cancer Institute
mi
from
Louisville, KY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Tufts Medical Center
mi
from
Boston, MA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Henry Ford Hospital
mi
from
Detroit, MI
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Spectrum Health
mi
from
Grand Rapids, MI
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Spectrum Health
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
John Nasseff Neuroscience Institute at Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
John Nasseff Neuroscience Institute at Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
ST. Luke's Hospital
mi
from
Kansas City, MO
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
ST. Luke's Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
The Brain Tumor Center at JFK Medical Center
mi
from
Edison, NJ
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
The Brain Tumor Center at JFK Medical Center
mi
from
Edison, NJ
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Overlook Hospital
mi
from
Summit, NJ
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Overlook Hospital
mi
from
Summit, NJ
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Capital Health Regional Medical Center
mi
from
Trenton, NJ
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Capital Health Regional Medical Center
mi
from
Trenton, NJ
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
The Long Island Brain Tumor Center at Neurological Surgery, P.C.
mi
from
Lake Success, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
The Long Island Brain Tumor Center at Neurological Surgery, P.C.
mi
from
Lake Success, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
North Shore University Hospital
mi
from
Manhasset, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials